Clinical efficacy of alendronate sodium combined with chemotherapy in patients with multiple myeloma
Objective To explore the effect of alendronate sodium combined with chemotherapy on osteocalcin(OC),type Ⅰ procollagen aminopeptide(PINP)and bone specific alkaline phosphatase(BAP)in patients with multiple myeloma.Methods A total of 72 patients with multiple myeloma from Qianjiang Central Hospital from February 2020 to February 2023 were retrospectively selected and divided into two groups according to treatment methods:alendronate sodium combined with chemotherapy group(observation group)and simple conventional chemotherapy group(control group),with 36 cases in each group.The β collagen specific sequence(βCTx),OC,PINP,blood calcium,blood phosphorus,alkaline phosphatase,BAP,immune function,clinical efficacy and occurrence of adverse reactions were statistically analyzed in the two groups.Results After treatment,the levels of βCTx and CD8+in the observation group were lower than those in the control group,and the levels of OC,BAP,PINP,CD3+,CD4+and CD4+/CD8+were higher than those in the control group,with statistical significance(P＜0.05).However,there was no statistically significant difference in the levels of blood phosphorus,blood calcium,and alkaline phosphatase between the two groups of patients(P＞0.05).The total remission rate in the observation group was 94.44％(34/36)higher than that in the control group,which was 44.44％(16/36),and the difference was statistically significant(P＜0.05).The total incidence of adverse reactions in the observation group was 5.56％(2/36),which was significantly lower than that in the control group(27.78％,10/36)(P＜0.05).Conclusion Compared with simple routine chemotherapy,alendronate sodium combined with chemotherapy in patients with multiple myeloma can improve the levels of OC,PINP and BAP and immune function,reduce the level of βCTx and reduce the incidence of adverse reactions.
Multiple myelomaAlendronate sodiumChemotherapyOsteocalcinBone specific alkaline phosphatase
万方数据
维普
